MOTS-C Canada: Mitochondrial-Derived Peptide Research Guide (2026)

By the ThePeptide Research Team · Independently verified ≥99% HPLC purity (Testides, Toronto; COA on product page) · Last updated August 2026

MOTS-C 10mg is a synthetic version of MOTS-c, a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S ribosomal RNA (MT-RNR1) gene. First described in 2015, MOTS-c has become one of the most studied MDPs in mitochondrial biology because published laboratory research links it to AMPK-dependent metabolic signalling, glucose handling, exercise physiology, and cellular responses to metabolic stress and aging. This guide summarizes what peer-reviewed studies actually report about MOTS-c as a research compound — strictly for in-vitro and laboratory investigation, with no human application implied.

What MOTS-C Is: Molecular Profile

MOTS-c (Mitochondrial ORF of the Twelve S rRNA type-c) is a small bioactive peptide of just 16 amino acids. Its distinguishing feature is where its genetic code lives: unlike most cellular peptides, which are encoded in the nucleus, MOTS-c is encoded by a short open reading frame within the mitochondrial 12S ribosomal RNA gene (MT-RNR1). This makes it a member of the mitochondrial-derived peptide (MDP) family — a class of molecules that reframed the mitochondrion as more than an energy factory, positioning it as a signalling hub that can talk to the rest of the cell and even to the nucleus.

For laboratory work, MOTS-c is produced by solid-phase peptide synthesis as a lyophilized (freeze-dried) powder and characterized by HPLC and mass spectrometry. The table below summarizes the core molecular facts most frequently cited in the primary literature.

Discovery & the Mitochondrial-Derived Peptide Class

MOTS-c was first described in 2015 by Changhan Lee, Pinchas Cohen, and colleagues at the University of Southern California, in a landmark paper in Cell Metabolism. The team identified a previously unrecognized open reading frame embedded in the mitochondrial 12S rRNA sequence and showed that the resulting 16-residue peptide was detectable in cells, tissues, and circulation — and that it carried metabolic activity rather than being an inert fragment.

MOTS-c joined humanin (the first MDP, described in 2001) and the SHLP (small humanin-like peptide) family as part of a growing catalogue of mitochondrial-encoded signalling molecules. The conceptual shift was significant: mitochondria were shown to encode peptides that act beyond the organelle itself, participating in what researchers describe as "mitonuclear" and even endocrine-like communication. This is why MOTS-c is frequently framed in reviews as a "mitochondrial hormone-like" signal, though that language describes a research concept, not an approved therapeutic role.

Mechanism: AMPK & Metabolic Signalling

The most consistently reported mechanism for MOTS-c centres on AMP-activated protein kinase (AMPK), a master sensor of cellular energy status. In the original Cell Metabolism work and subsequent reviews, MOTS-c is described as targeting the folate–methionine one-carbon cycle. By interfering with folate-dependent purine biosynthesis, MOTS-c promotes accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous AMPK activator. Elevated AICAR in turn activates AMPK, which shifts cells toward energy-conserving, catabolic programs — increased glucose uptake and altered fuel utilization.

Nuclear translocation under stress

A second, widely cited feature is that under metabolic stress (for example, glucose restriction or oxidative challenge), MOTS-c translocates from the cytoplasm to the nucleus in an AMPK-dependent manner. There it is reported to associate with stress-responsive transcription factors, including regulators tied to the antioxidant response element (ARE) and NRF2-linked pathways, modulating expression of genes involved in antioxidant defence and metabolic adaptation. This gives MOTS-c an unusual dual identity in the literature: a cytoplasmic metabolic effector and a stress-inducible regulator of nuclear gene expression.

What the Research Shows

The following summaries reflect findings reported in published cell-culture and animal studies. They describe experimental observations in laboratory models, not effects in humans.

Metabolic homeostasis & obesity models

In the founding 2015 study, MOTS-c was reported to reduce diet-induced obesity and improve metabolic parameters in mouse models, with the peptide framed as a promoter of metabolic homeostasis. Reviews since then consistently describe MOTS-c as protective against metabolic dysfunction in rodent high-fat-diet paradigms.

Insulin sensitivity & glucose metabolism

MOTS-c is repeatedly associated with enhanced insulin sensitivity and improved glucose uptake in skeletal muscle in preclinical models, consistent with its proposed AMPK-driven mechanism. A 2025 study in Experimental & Molecular Medicine reported that MOTS-c helped prevent pancreatic islet-cell senescence in a diabetes model, extending the metabolic research narrative to β-cell biology.

Exercise-mimetic signalling

Because AMPK activation overlaps with the metabolic signature of physical activity, MOTS-c is frequently described as having "exercise-mimetic" properties in the laboratory — that is, it engages some of the same energy-sensing pathways that exercise recruits.

Aging & cellular stress

Reviews of MOTS-c in aging biology connect its declining circulating levels with age to research interest in mitochondrial function during aging and age-related metabolic decline. These remain associations observed in research settings, not demonstrated clinical outcomes.

MOTS-C, Exercise & Mitochondria

One of the most influential MOTS-c papers is Reynolds and colleagues' 2021 study in Nature Communications, which characterized MOTS-c as an exercise-induced, mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. In that work, physical activity increased MOTS-c expression, and the peptide was implicated in muscle metabolic adaptation. Related reports note that exercise can raise circulating MOTS-c roughly 1.5–1.6-fold, reinforcing the picture of MOTS-c as part of the body's response to metabolic demand.

Because MOTS-c is mitochondrially encoded, its biology is also studied in the context of mitochondrial density and function in metabolically active tissues such as skeletal muscle, tying together the peptide's energy-sensing role with broader questions about how mitochondria coordinate whole-cell metabolism.

Genetics, Aging & Longevity Signals

MOTS-c research has a notable human-genetics thread. A naturally occurring MOTS-c variant, K14Q (a lysine-to-glutamine substitution arising from an m.1382A>C polymorphism in the 12S rRNA region), has been examined in East Asian cohorts. Fuku and colleagues raised the question of MOTS-c as "a player in exceptional longevity" in Aging Cell (2015), and later work associated the K14Q variant with type 2 diabetes risk in Japanese men with lower physical activity, and with sarcopenia and lipid measures in older Korean adults. Together these studies keep MOTS-c genetics active in aging and metabolic research, while also illustrating that the peptide's biology can differ between populations and variants.

A recurring observation across aging studies is that MOTS-c levels tend to be higher in younger individuals and lower with advancing age, which is one reason MOTS-c appears frequently in longevity-focused mitochondrial research. These are descriptive research findings — they do not establish that manipulating MOTS-c changes lifespan or health in humans.

Honest Limits: Preclinical vs Human

Responsible sourcing means being candid about what is not established. The MOTS-c evidence base has real strengths and real gaps:

• Mostly preclinical. The great majority of mechanistic and outcome data come from cell culture and rodent models. Robust, large-scale human clinical trials are limited.
• Translation is uncertain. Effects observed in mice do not automatically hold in humans, and pharmacokinetics and long-term profiles in people are not well defined.
• Variant and context dependence. The K14Q findings show MOTS-c biology can vary by genetic background and by factors such as physical activity level.
• Measurement challenges. As a small mitochondrial-derived peptide, MOTS-c can be difficult to quantify reliably, and assay differences complicate cross-study comparison.
• Regulatory status. MOTS-c is not an approved drug or supplement. It is a research chemical. It was added to the World Anti-Doping Agency prohibited list in 2024, which is relevant context for anyone tracking the compound.

For these reasons, MOTS-c should be treated as an investigational tool for in-vitro laboratory research — a compound to study, not to use.

Purity, Third-Party Testing & Handling for Research

For peptide research, the quality of the raw material determines the quality of the data. Small differences in purity, counter-ion content, or peptide content can meaningfully shift experimental results. Every batch of our MOTS-C 10mg is verified to ≥99% purity by HPLC, with identity confirmed by mass spectrometry, and the corresponding Certificate of Analysis (COA) is published on the product page.

What to look for on a COA

• HPLC chromatogram establishing purity (≥99%).
• Mass-spec confirmation that the measured mass matches the expected 2,174.62 Da for the 16-mer.
• Batch / lot number traceable to the vial you receive.
• Independent testing — ours is verified by Testides (Toronto).

Storage of the sealed vial

Sealed, unopened vials of lyophilized MOTS-c are generally stored cold and protected from light and moisture. This page does not provide preparation, solution, or administration instructions of any kind. Qualified laboratories are responsible for following their own institutional protocols and the documentation supplied with the material. Nothing on this page is an instruction for human or animal use.

Sourcing MOTS-C in Canada

For Canadian laboratories and independent researchers, buying domestically removes the friction of international shipping, customs delays, and cold-chain uncertainty. MOTS-C 10mg ships from within Canada, so orders move through domestic post without a border crossing, and pricing is listed in CAD ($59.99 for the 10 mg vial) with no surprise conversion or import handling at delivery. Shipping is free and tracked Canada-wide, with no minimum order.

Beyond logistics, the practical advantages for research buyers are transparency and traceability: a batch-specific COA is available on the product page, purity is independently verified at ≥99% by HPLC (Testides, Toronto), and each vial is lot-numbered. That documentation is what lets a researcher tie an experiment back to a known, characterized material — the baseline requirement for reproducible in-vitro work.

Research Use Only. This product and page are provided solely for in-vitro laboratory and scientific research. Not for human or veterinary use, ingestion, or administration. No statement here has been evaluated by Health Canada or any regulatory agency, and nothing here is medical advice or a therapeutic claim.